Immunocore announced that Brian Di Donato has been appointed as Chief Financial Officer and Head of Strategy, with immediate effect. Brian has more than 20 years of financial and leadership experience and will be responsible for Immunocore's corporate strategy, finance and investor relations. Most recently, Brian was Senior Vice President and Chief Financial Officer at Achillion Pharmaceuticals Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.12 USD | -2.28% |
|
-13.35% | -48.59% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.59% | 1.8B | |
+51.99% | 803B | |
-5.72% | 351B | |
+18.94% | 324B | |
+11.07% | 303B | |
+16.96% | 243B | |
+2.25% | 228B | |
+11.15% | 217B | |
+7.59% | 164B | |
-3.65% | 155B |
- Stock Market
- Equities
- IMCR Stock
- News Immunocore Holdings plc
- Immunocore Appoints Brian Di Donato as Chief Financial Officer and Head of Strategy